Targets › CNGA3
1 program from 1 company in 1 trial: 1 Phase 1; Ophthalmology; next expected readout Jun 2027.
Pore-forming subunit of the cone cyclic nucleotide-gated channel. Mediates cone photoresponses at bright light converting transient changes in intracellular cGMP levels into electrical signals. (UniProt, Q16281)
Open in Phaseline: the race on CNGA3, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| STZ eyetrial | rAAV.hCNGA3 Recombinant adeno-associated virus vector delivering human CNGA3 gene for gene therapy of | CNGA3 | Phase 1 | Achromatopsia | Jun 2027 |
Achromatopsia (1)
small molecule (1)
STZ eyetrial (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.